MS Observational Study

What is the study?

In a collaborative effort with Biogen and Brigham and Women’s Hospital, we are supporting a study to decipher why multiple sclerosis (MS) progresses so differently among diagnosed individuals and to glean insights that could inform new therapies and improve care for all MS patients.

How are you making it happen?

Our program builds on the Brigham and Women’s Hospital's Comprehensive Longitudinal Investigation of MS (CLIMB) Study, a longitudinal study of patients with MS. Ongoing research initiatives to harness the power of big data and offer insights into new treatment possibilities and more individualized care include a study analyzing clinical, radiological and biological data collected from MS patients to identify the main factors associated with the severity and progression of the disease. Another study is testing the feasibility of a wearable device developed by Verily to measure the mobility, gait and dexterity of MS patients.

The initiatives combine wearable sensors with traditional clinical tests and lab-based tests designed to gather and analyze biological, physiological, behavioral and environmental variables. With this data, our software team can use machine learning algorithms and other computational techniques to generate insights. The goal is to identify clinical, radiological, biological, behavioral and environmental factors that correlate with MS disease severity and progression.

Learn more in our newsroom